1. Redefining Hypo- and Hyper-Responding Phenotypes of CFTR Mutants for Understanding and Therapy
- Author
-
Tamara Hillenaar, Jeffrey Beekman, Peter van der Sluijs, and Ineke Braakman
- Subjects
CFTR ,protein folding ,modulators ,hypo-responding mutants ,hyper-responders ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Mutations in CFTR cause misfolding and decreased or absent ion-channel function, resulting in the disease Cystic Fibrosis. Fortunately, a triple-modulator combination therapy (Trikafta) has been FDA-approved for 178 mutations, including all patients who have F508del on one allele. That so many CFTR mutants respond well to modulators developed for a single mutation is due to the nature of the folding process of this multidomain protein. We have addressed the question ‘What characterizes the exceptions: the mutants that functionally respond either not or extremely well’. A functional response is the product of the number of CFTR molecules on the cell surface, open probability, and conductivity of the CFTR chloride channel. By combining biosynthetic radiolabeling with protease-susceptibility assays, we have followed CF-causing mutants during the early and late stages of folding in the presence and absence of modulators. Most CFTR mutants showed typical biochemical responses for each modulator, such as a TMD1 conformational change or an increase in (cell-surface) stability, regardless of a functional response. These modulators thus should still be considered for hypo-responder genotypes. Understanding both biochemical and functional phenotypes of outlier mutations will boost our insights into CFTR folding and misfolding, and lead to improved therapeutic strategies.
- Published
- 2022
- Full Text
- View/download PDF